Tag: predictive biomarkers market share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Predictive Biomarkers Market Revenue Growth On Track For A 4% CAGR Through 2030

The predictive biomarkers market has experienced consistent expansion in recent years. It is anticipated to increase from $20.96 billion in 2025 to $21.88 billion in 2026, progressing at a compound annual growth rate (CAGR) of 4.4%. The historical growth of this market can be ascribed to factors like growth in genomic research, rise in targeted therapies, increasing cancer prevalence, expansion of molecular diagnostics, and regulatory support for biomarkers.

The predictive biomarkers market is projected to experience consistent expansion in the coming years. It is anticipated to reach $25.65 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 4.0%. This growth during the forecast period is driven by factors such as progress in multi-omics technologies, the broadening scope of personalized medicine, increased pharmaceutical research and development expenditure, the need for predictive treatment results, and the incorporation of biomarkers into standard healthcare practices. Key developments expected over the forecast horizon involve the wider application of precision oncology, an increase in their utility for drug response stratification, more biomarker-driven clinical trial designs, the growing uptake of companion diagnostics, and the establishment of standardized biomarker validation protocols.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=29551976&type=smp&name=Predictive%20Biomarkers%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Predictive Biomarkers Market Growth Drivers: What’s Behind The Acceleration?

The increasing incidence of cancer is anticipated to fuel the expansion of the predictive biomarkers market moving ahead. Cancer is defined by the uncontrolled proliferation of cells, which have the capacity to invade and metastasize to other bodily regions. This surge in cancer cases stems mainly from an aging global demographic, evolving lifestyle habits, and heightened exposure to risk elements like tobacco, poor dietary choices, and environmental contaminants. Within oncology, predictive biomarkers are instrumental in pinpointing patients who are probable candidates for particular treatments, thus facilitating personalized and more efficacious therapeutic strategies. For example, a report from April 2024 by the International Agency for Research in Cancer (IARC), a specialized France-based World Health Organization (WHO) agency dedicated to cancer research, indicated that 2022 saw nearly 20 million new cancer diagnoses and approximately 10 million deaths attributed to cancer. Furthermore, forecasts indicate that the yearly count of new cancer cases is set to escalate to 35 million by 2050, signifying a 77% increase compared to 2022 figures. Consequently, the escalating number of cancer cases is poised to propel the predictive biomarkers market’s growth.

Predictive Biomarkers Market Segment Analysis Spotlighting Growth Areas

The predictive biomarkers market covered in this report is segmented –

1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications

2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring

3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users

Subsegments:

1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer

2) By Metabolic Disease: Type 1 And Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance

3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease

4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (Ibd), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (Copd), Immunodeficiency Disorders

5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders

Predictive Biomarkers Market Trends: What’s Defining The Industry’s Next Phase?

Leading firms within the predictive biomarkers market are prioritizing the speed of biomarker development, leveraging technological progress such as artificial intelligence (AI)-driven biomarker discovery. This strategy aims to secure a competitive advantage by delivering more tailored and potent treatments at an accelerated pace. Through AI-driven biomarker discovery, extensive and intricate datasets can be analyzed, uncovering predictive biomarkers that traditional approaches might miss. An illustration of this is the July 2024 launch by Scipher Medicine, Inc., a precision immunology company based in the US, of their PRoBeNet (Predictive Response Biomarkers using Network Medicine). The objective of PRoBeNet is to hasten the creation of predictive response biomarkers for intricate diseases, utilizing AI and network biology. It functions by pinpointing therapy response biomarkers through the combination of therapy-targeted proteins and distinct molecular signatures associated with diseases. Validated for autoimmune conditions like rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, its application extends to additional complex diseases and various stages of drug development.

Predictive Biomarkers Market Top Companies Driving Competitive Growth

Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc

View The Full Predictive Biomarkers Market Report:

https://thebusinessresearchcompany.com/report/predictive-biomarkers-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Predictive Biomarkers Market Global Footprint: Which Region Leads The Industry?

North America was the largest region in the predictive biomarkers market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The predictive biomarkers market is witnessing steady growth driven by rapid advancements in medical research and technology. As the importance of personalized healthcare rises, predictive biomarkers are becoming essential tools in early disease detection and tailored treatment strategies. Let’s explore the current market size, key factors influencing growth, prominent industry players, and emerging trends shaping this evolving sector.

Predictive Biomarkers Market Size and Growth Expectations

The predictive biomarkers market has steadily expanded over recent years and is projected to continue this trend. The market size is expected to increase from $20.96 billion in 2025 to $21.88 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.4%. Looking ahead, it is forecasted to reach $25.65 billion by 2030 with a CAGR of 4.0%. Historical growth is primarily driven by advancements in genomic research, expanding use of targeted therapies, rising cancer prevalence, growth in molecular diagnostics, and supportive regulatory frameworks. Future growth will be influenced by innovations in multi-omics technologies, broader adoption of personalized medicine, increased pharmaceutical R&D investments, demand for predictive treatment outcomes, and greater integration of biomarkers into routine clinical care. Key trends expected to shape the market include expanded applications in precision oncology, increased use in drug response stratification, greater reliance on biomarker-driven clinical trial designs, rising uptake of companion diagnostics, and efforts toward standardizing biomarker validation processes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20595&type=smp

Rising Cancer Incidence as a Major Growth Catalyst

One of the primary drivers propelling the predictive biomarkers market is the increasing incidence of cancer worldwide. Cancer, characterized by uncontrolled cell proliferation and the potential to spread throughout the body, is becoming more prevalent due to factors such as aging populations, lifestyle shifts, and heightened exposure to risk factors including tobacco use, unhealthy diets, and environmental pollution. Predictive biomarkers play a crucial role in identifying patients who are likely to benefit from specific therapies, facilitating more precise and effective treatment approaches. For example, the International Agency for Research on Cancer (IARC), a specialized cancer research agency within the World Health Organization (WHO), reported nearly 20 million new cancer cases and about 10 million cancer-related deaths in 2022. Furthermore, projections suggest that new cancer cases could rise to 35 million annually by 2050, marking a 77% increase from 2022 figures. This escalating cancer burden significantly contributes to the growing demand for predictive biomarkers.

Key Segments and Revenue Drivers in the Predictive Biomarkers Market

This report segments the predictive biomarkers market by indication, application, and end user to provide a comprehensive overview:

1) Indication categories include Cancer, Metabolic Diseases, Cardiovascular Disorders, Immunological Disorders, and Other Indications.

2) Application areas encompass Screening, Analysis, Diagnosis, Prediction, and Monitoring.

3) End users cover Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharmaceutical and Biotechnology Companies, and other users.

Access The Complete Predictive Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/predictive-biomarkers-global-market-report

Within the cancer category, subtypes analyzed include Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia and Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, and Head and Neck Cancer. The metabolic disease segment covers Type 1 and 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, and Insulin Resistance. Cardiovascular disorders include Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction, Arrhythmia, Hypertension, Stroke, and Peripheral Arterial Disease. Immunological disorders involve Autoimmune Diseases, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Immunodeficiency Disorders. Other indications cover Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, and Respiratory Disorders.

Technological Innovations Driving Market Transformation

Leading companies in the predictive biomarkers field are increasingly leveraging technological breakthroughs to accelerate biomarker development and gain a competitive edge. A prominent innovation is the use of artificial intelligence (AI) for biomarker discovery, which enables the analysis of vast and complex datasets to pinpoint predictive biomarkers that traditional approaches might miss. For example, in July 2024, Scipher Medicine, Inc., a US-based precision immunology company, introduced PRoBeNet (Predictive Response Biomarkers using Network Medicine). This AI-powered platform aims to speed up the identification of predictive response biomarkers for complex diseases by integrating therapy-targeted proteins with disease-specific molecular signatures. PRoBeNet has been validated for autoimmune conditions such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, and its application extends to other complex diseases and various drug development stages.

Leading Players Steering Competition in the Predictive Biomarkers Space

The predictive biomarkers market features several prominent organizations that are driving innovation and competition. Key companies operating in this space include Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, and Biomarker Technologies Inc.

Regional Market Dynamics Highlighting Growth Opportunities

In 2025, North America was the largest regional market for predictive biomarkers, supported by strong healthcare infrastructure and investment in biomedical research. Meanwhile, Europe is expected to experience the fastest growth during the coming years. The overall regional analysis includes Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, offering a broad perspective on global market opportunities and trends.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Predictive Biomarkers Market During 2026–2030?

The predictive biomarkers market has experienced consistent growth in recent years. Its valuation is set to rise from $20.96 billion in 2025 to $21.88 billion by 2026, achieving a compound annual growth rate (CAGR) of 4.4%. Historically, this expansion has been propelled by factors including the advancement of genomic research, an increase in targeted therapies, the growing prevalence of cancer, the wider adoption of molecular diagnostics, and supportive regulatory environments for biomarkers.

The predictive biomarkers market is anticipated to experience consistent expansion over the coming years. By 2030, this market is projected to reach $25.65 billion, demonstrating a compound annual growth rate (CAGR) of 4.0%. This anticipated growth during the forecast period is attributable to several factors, including advancements in multi-omics technologies, the widening scope of personalized medicine, increased pharmaceutical research and development expenditures, a rising demand for predictable treatment outcomes, and the integration of biomarkers into standard healthcare practices. Key trends expected within this period involve the expansion of precision oncology applications, increased utilization in stratifying drug responses, a greater emphasis on biomarker-based clinical trial designs, the growing adoption of companion diagnostics, and the standardization of biomarker validation protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20595&type=smp

What Underlying Factors Are Accelerating The Growth Of The Predictive Biomarkers Market?

The increasing incidence of cancer is anticipated to propel the expansion of the predictive biomarkers market in the coming years. Cancer is defined as a disease marked by uncontrolled cell growth capable of invading and spreading to other parts of the body. The escalation in cancer cases is primarily attributable to aging populations, shifts in lifestyle, and greater exposure to risk factors such as tobacco, unhealthy diets, and environmental pollutants. Predictive biomarkers in oncology are instrumental in identifying patients who are likely to respond to specific treatments, thereby facilitating personalized and more effective therapy. For instance, in April 2024, a report from the International Agency for Research on Cancer (IARC), a France-based specialized agency of the World Health Organization (WHO) dedicated to cancer research, revealed nearly 20 million new cancer cases and approximately 10 million cancer-related deaths occurred in 2022. Furthermore, projections indicate that the annual number of new cancer cases is expected to increase to 35 million by 2050, signifying a 77% rise from 2022 levels. Consequently, the increasing prevalence of cancer will drive the growth of the predictive biomarkers market.

How Are The Various Segments Of The Predictive Biomarkers Market Categorized?

The predictive biomarkers market covered in this report is segmented –

1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications

2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring

3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users

Subsegments:

1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer

2) By Metabolic Disease: Type 1 And Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance

3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease

4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (Ibd), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (Copd), Immunodeficiency Disorders

5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders

What Trends Are Affecting The Expansion Of The Predictive Biomarkers Market?

Companies operating within the predictive biomarkers market are prioritizing the acceleration of biomarker development through technological advancements, such as artificial intelligence (AI)-driven biomarker discovery, aiming to gain a competitive edge by delivering more personalized and effective therapies faster. AI-driven biomarker discovery facilitates the analysis of extensive, complex datasets, leading to the identification of predictive biomarkers that might not be evident through conventional methods. For instance, in July 2024, Scipher Medicine, Inc., a US-based precision immunology company, introduced PRoBeNet (Predictive Response Biomarkers using Network Medicine). This system aims to expedite the development of predictive response biomarkers for complex diseases using AI and network biology. PRoBeNet identifies biomarkers of therapy response by integrating therapy-targeted proteins and disease-specific molecular signatures. Its validation has occurred for autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, with potential application to other complex diseases and drug development phases.

Which Major Firms Influence Developments In The Predictive Biomarkers Market?

Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc

Read the full predictive biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/predictive-biomarkers-global-market-report

Which Region Is Projected To Dominate The Predictive Biomarkers Market During The Forecast Period?

North America was the largest region in the predictive biomarkers market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Predictive Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20595&type=smp

Browse Through More Reports Similar to the Global Predictive Biomarkers Market 2026, By The Business Research Company

Renal Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Non Alcoholic Steatohepatitis Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Predictive Biomarkers Market from 2026 to 2030?

The predictive biomarkers market has demonstrated consistent expansion in recent years. Its valuation is set to climb from $20.96 billion in 2025 to $21.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.4%. This market’s past growth can be attributed to several factors including growth in genomic research, the rise in targeted therapies, increasing cancer prevalence, the expansion of molecular diagnostics, and regulatory support for biomarkers.

The predictive biomarkers market is anticipated to experience consistent expansion over the upcoming years, with its valuation projected to reach $25.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.0%. This projected growth during the forecast timeframe is attributable to several factors, including breakthroughs in multi-omics technologies, the broadening scope of personalized medicine, rising pharmaceutical research and development expenditure, a growing need for anticipatory treatment results, and the incorporation of biomarkers into standard medical practices. Key trends anticipated during this period encompass the wider application of precision oncology, an expanding role in stratifying drug responses, the increased design of clinical trials leveraging biomarkers, the growing uptake of companion diagnostics, and the establishment of standardized protocols for biomarker validation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20595&type=smp

What Drivers Are Affecting Demand In The Predictive Biomarkers Market?

An anticipated increase in cancer incidents is set to fuel the expansion of the predictive biomarkers market. Cancer, a condition marked by uncontrolled cellular proliferation, can metastasize and affect various bodily regions. This surge in cancer cases primarily stems from demographic shifts towards older populations, evolving lifestyles, and heightened exposure to risk elements like tobacco use, poor dietary habits, and environmental contaminants. Within oncology, predictive biomarkers facilitate the identification of patients who are probable responders to particular treatments, thereby enabling tailored and more efficacious therapeutic interventions. For example, a report from April 2024 by the International Agency for Research on Cancer (IARC), a specialized cancer research agency based in France under the World Health Organization (WHO), indicated that 2022 saw almost 20 million new cancer cases and roughly 10 million cancer-related fatalities. Furthermore, forecasts predict the yearly count of new cancer cases will ascend to 35 million by 2050, which represents a 77% increment compared to 2022 figures. Consequently, the increasing incidence of cancer will be a key impetus for the expansion of the predictive biomarkers market.

Which Segments Are Gaining Traction In The Predictive Biomarkers Market?

The predictive biomarkers market covered in this report is segmented –

1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications

2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring

3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users

Subsegments:

1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer

2) By Metabolic Disease: Type 1 And Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance

3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease

4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (Ibd), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (Copd), Immunodeficiency Disorders

5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders

Which Competitive Trends Are Impacting The Structure Of The Predictive Biomarkers Market?

Leading companies within the predictive biomarkers market are prioritizing the acceleration of biomarker development through technological innovations, such as artificial intelligence (AI)-driven biomarker discovery, to secure a competitive advantage by delivering more tailored and effective treatments expeditiously. AI-driven biomarker discovery facilitates the analysis of vast, intricate datasets, enabling the identification of predictive biomarkers that might not be discernible through conventional methods. For example, in July 2024, Scipher Medicine, Inc., a US-based precision immunology company, introduced PRoBeNet (Predictive Response Biomarkers using Network Medicine). This initiative aims to expedite the creation of predictive response biomarkers for complex illnesses by leveraging AI and network biology. PRoBeNet identifies biomarkers indicating therapy response by consolidating therapy-specific proteins and disease-characteristic molecular signatures. It has undergone validation for autoimmune conditions including rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, and its application can be extended to other complex diseases and various phases of drug development.

Who Are The Top-Performing Companies In The Predictive Biomarkers Market In Recent Years?

Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/predictive-biomarkers-global-market-report

How Does The Predictive Biomarkers Market Perform Across Major Global Regions?

North America was the largest region in the predictive biomarkers market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Predictive Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20595&type=smp

Browse Through More Reports Similar to the Global Predictive Biomarkers Market 2026, By The Business Research Company

Renal Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Non Alcoholic Steatohepatitis Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Discover trends, market shifts, and competitive outlooks for the predictive biomarkers industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Predictive Biomarkers Market Growth Evolved From 2024 To 2025, And What’s Ahead?

There has been a consistent expansion in the size of the predictive biomarkers market in the past few years. The market size is set to increase from $20.05 billion in 2024 to $20.96 billion in 2025, projecting a compound annual growth rate (CAGR) of 4.5%. Various factors contributing to this growth during the historic period include the surge in research and development investments, improvement in healthcare infrastructure, partnerships between educational institutes and the industry, an upward trend in the occurrence of cancer and genetic diseases, and the escalated usage of biomarkers in the process of drug development.

It is projected that within several years, the predictive biomarkers market size will experience a consistent expansion. The market is anticipated to climb to $24.67 billion by 2029, with a compound annual growth rate (CAGR) of 4.2%. The progression during the forecast period can be linked to the growing acceptance of precision medicine, heightened attention towards preventive healthcare, an uptick in healthcare spending, additional investments in biomarker-focused diagnostics, the establishment of more biobanks and tissue repositories, and an increase in global health consciousness. The dominant trends expected in the forecast period encompass the incorporation of artificial intelligence into biomarker analysis, the advent of non-invasive biomarker testing, progress in digital health tools based on biomarkers, advancements in single-cell sequencing technologies, the development of real-time biosensing and monitoring systems, and improvements in bioinformatics tools for data integration.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20595&type=smp

What Are the Core Growth Drivers Propelling the Predictive Biomarkers Market Forward?

The predictive biomarkers market’s expansion is anticipated to be driven by the surge in cancer cases. Cancer, a disease typified by unchecked cell growth that can spread to other parts of the body, is primarily on the rise due to the aging population, lifestyle modifications, and increased exposure to risk factors like tobacco use, unhealthy dietary habits, and environmental toxins. Predictive biomarkers in cancer assist in recognizing patients who are likely to respond positively to certain treatments, thereby facilitating personalized and more efficient therapy. For example, as stated in a report from the International Agency for Research on Cancer (IARC), a specialized cancer research agency under the World Health Organization (WHO) based in France, in April 2024 there were almost 20 million new cancer cases and roughly 10 million cancer-related fatalities in 2022. Moreover, it is projected that the yearly count of new cancer cases will reach 35 million by 2050, signifying a 77% climb from the 2022 figures. Hence, the escalating occurrence of cancer will fuel the predictive biomarkers market’s growth.

What Segment Types Define the Predictive Biomarkers Market Structure?

The predictive biomarkers market covered in this report is segmented –

1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications

2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring

3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users

Subsegments:

1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer

2) By Metabolic Disease: Type 1 and Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance

3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease

4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Immunodeficiency Disorders

5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20595&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Predictive Biomarkers Market?

North America was the largest region in the predictive biomarkers market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Predictive Biomarkers Market?

Leading firms in the predictive biomarkers market are investing in accelerating biomarker development through innovative technology, including AI-facilitated biomarker discovery. This strategy empowers these firms to stay competitive by delivering more customized and efficient treatments quickly. AI-facilitated biomarker discovery allows for large and intricate dataset analysis, potentially identifying predictive biomarkers that traditional techniques may not detect. For instance, Scipher Medicine, Inc., a US-based firm specializing in precision immunology, initiated a PRoBeNet (Predictive Response Biomarkers using Network Medicine) in July 2024. Its primary objective is to speed up the development of predictive response biomarkers for complex diseases through AI and network biology. PRoBeNet detects therapy response biomarkers by merging therapy-targeted proteins and disease-specific molecular patterns. Its effectiveness has been proven in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, and it shows promise for application in other complex diseases and drug development stages.

View the full report here:

https://www.thebusinessresearchcompany.com/report/predictive-biomarkers-global-market-report

What Is the Definition of the Predictive Biomarkers Market?

Predictive biomarkers refer to biological indicators that help predict an individual’s likelihood of developing a disease or their response to a specific treatment. They can be genetic, proteomic, or molecular markers that provide insights into disease susceptibility or treatment efficacy and the advantage of tailoring treatments to individual patients, enhancing the effectiveness of interventions, and potentially reducing adverse effects by identifying those most likely to benefit from specific therapies.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20595

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model